Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography

被引：12
|
作者：
Hutchinson, OC [1 ]
Collingridge, DR [1 ]
Barthel, H [1 ]
Price, PM [1 ]
Aboagye, EO [1 ]
机构：
[1] Hammersmith Hosp, Imperial Coll Sch Med, Sec Canc Therapeut, CRC PET Oncol Grp, London W12 0NN, England
来源：
CURRENT PHARMACEUTICAL DESIGN | 2003年 / 9卷 / 11期
关键词：
D O I：
10.2174/1381612033455288
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Positron emission tomography (PET) provides the oncologist with information on tumour diagnosis, and treatment response monitoring. Mathematical modelling of tissue data, and online plasma radioactive metabolite profiling, enables important tissue kinetic parameters relating to the uptake, distribution and washout as well as arterial input function to be derived. The resultant kinetic data allow for not only diagnosis but also the assessment of therapeutic response endpoints. These endpoints can be used to measure specific therapeutic effects. This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N - [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide and 5-fluorouracil (5-FU) are described.
引用
收藏
页码：917 / 929
页数：13
相关论文
共 50 条
  • [1] Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography
    Hutchinson, OC
    Collingridge, DR
    Barthel, H
    Price, PM
    Aboagye, EO
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (11) : 931 - 944
  • [2] Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology
    Rangger, Christine
    Haubner, Roland
    [J]. PHARMACEUTICALS, 2020, 13 (02)
  • [3] Dynamic Analysis of Pharmacokinetics of Orally Administered Drugs Using Positron Emission Tomography
    Kataoka, Makoto
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2012, 132 (08): : 911 - 917
  • [4] Development of targeted radiopharmaceuticals and radiolabelled nanoparticles for positron emission tomography imaging
    Archibald, Steve
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2015, 58 (04): : 150 - 150
  • [5] Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods
    Tolmachev, Vladimir
    Stone-Elander, Sharon
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2010, 1800 (05): : 487 - 510
  • [6] Use of positron emission tomography in anticancer drug development
    Aboagye, EO
    Price, PM
    [J]. INVESTIGATIONAL NEW DRUGS, 2003, 21 (02) : 169 - 181
  • [7] Use of Positron Emission Tomography in Anticancer Drug Development
    Eric O. Aboagye
    Patricia M. Price
    [J]. Investigational New Drugs, 2003, 21 : 169 - 181
  • [8] Regulation of the compounding of positron emission tomography drugs
    Hung, JC
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (02) : 134 - 139
  • [9] Radiolabelled tyrosine for the measurement of protein synthesis rate in vivo by positron emission tomography
    Paans, AMJ
    Pruim, J
    VanWaarde, A
    Willemsen, ATM
    Vaalburg, W
    [J]. BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1996, 10 (04): : 497 - 510
  • [10] Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
    Dolle, Frederic
    Luus, Christopher
    Reynolds, Aaron
    Kassiou, Michael
    [J]. CURRENT MEDICINAL CHEMISTRY, 2009, 16 (22) : 2899 - 2923
12345